Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

A Rogier van der Velde; Chris P H Lexis; Wouter C Meijers; Iwan C van der Horst; Erik Lipsic; Martin M Dokter; Dirk J van Veldhuisen; Pim van der Harst; Rudolf A de Boer

doi:10.1016/j.cca.2015.10.034

Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

A Rogier van der Velde, Chris P H Lexis, Wouter C Meijers, Iwan C van der Horst, Erik Lipsic, Martin M Dokter, Dirk J van Veldhuisen, Pim van der Harst, Rudolf A de Boer

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Fibrosis is a pivotal event in infarct repair and progressive remodeling after myocardial infarction (MI). Biomarkers may be used to monitor fibrosis, and therefore we evaluated the predictive value of galectin-3 and sST2 for cardiac remodeling after MI.

METHODS: Plasma galectin-3 and sST2 were measured in patients admitted with primary percutaneous coronary intervention (PCI) for acute MI, at baseline and at 4months. Left ventricular ejection fraction (LVEF) and infarct size were measured after 4months with cardiac MRI (CMR).

RESULTS: In total, 247 patients had blood samples and CMR data available (mean age 57.7±11.6years; 79.8% male). Increased baseline galectin-3 (≥17.8ng/mL) identified patients with lower LVEF (50.3% (±9.1) vs. non-elevated galectin-3 55.0% (±8.0); P<0.001), and larger infarct size (13.8g. (±12.9) vs. 8.6g. (±8.7); P=0.002) after 4months. Elevated sST2 (≥35.0ng/mL) did not predict decreased LVEF or larger infarct size. Furthermore we showed that at baseline, galectin-3 was an independent predictor for LVEF (β=-0.18; P=0.005) and infarct size (β=0.18; P=0.004). We repeated the analyses using median values of galectin-3 (13.4ng/mL) and sST2 (30.3ng/mL) as a cut point, and this validated our results.

CONCLUSION: The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI.

Original language	English
Pages (from-to)	50-7
Number of pages	8
Journal	Clinica Chimica Acta
Volume	452
DOIs	https://doi.org/10.1016/j.cca.2015.10.034
Publication status	Published - 15 Jan 2016
Externally published	Yes

Keywords

Biomarkers/blood
Blood Proteins
Double-Blind Method
Female
Galectin 3/blood
Galectins
Humans
Interleukin-1 Receptor-Like 1 Protein
Magnetic Resonance Imaging
Male
Middle Aged
Myocardial Infarction/blood
Receptors, Cell Surface/blood
Solubility
Time Factors
Ventricular Dysfunction, Left/blood

Access to Document

10.1016/j.cca.2015.10.034

Cite this

@article{39757baef5434c17a6419bb59d375d1f,

title = "Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction",

abstract = "BACKGROUND: Fibrosis is a pivotal event in infarct repair and progressive remodeling after myocardial infarction (MI). Biomarkers may be used to monitor fibrosis, and therefore we evaluated the predictive value of galectin-3 and sST2 for cardiac remodeling after MI.METHODS: Plasma galectin-3 and sST2 were measured in patients admitted with primary percutaneous coronary intervention (PCI) for acute MI, at baseline and at 4months. Left ventricular ejection fraction (LVEF) and infarct size were measured after 4months with cardiac MRI (CMR).RESULTS: In total, 247 patients had blood samples and CMR data available (mean age 57.7±11.6years; 79.8% male). Increased baseline galectin-3 (≥17.8ng/mL) identified patients with lower LVEF (50.3% (±9.1) vs. non-elevated galectin-3 55.0% (±8.0); P<0.001), and larger infarct size (13.8g. (±12.9) vs. 8.6g. (±8.7); P=0.002) after 4months. Elevated sST2 (≥35.0ng/mL) did not predict decreased LVEF or larger infarct size. Furthermore we showed that at baseline, galectin-3 was an independent predictor for LVEF (β=-0.18; P=0.005) and infarct size (β=0.18; P=0.004). We repeated the analyses using median values of galectin-3 (13.4ng/mL) and sST2 (30.3ng/mL) as a cut point, and this validated our results.CONCLUSION: The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI.",

keywords = "Biomarkers/blood, Blood Proteins, Double-Blind Method, Female, Galectin 3/blood, Galectins, Humans, Interleukin-1 Receptor-Like 1 Protein, Magnetic Resonance Imaging, Male, Middle Aged, Myocardial Infarction/blood, Receptors, Cell Surface/blood, Solubility, Time Factors, Ventricular Dysfunction, Left/blood",

author = "{van der Velde}, {A Rogier} and Lexis, {Chris P H} and Meijers, {Wouter C} and {van der Horst}, {Iwan C} and Erik Lipsic and Dokter, {Martin M} and {van Veldhuisen}, {Dirk J} and {van der Harst}, Pim and {de Boer}, {Rudolf A}",

year = "2016",

month = jan,

day = "15",

doi = "10.1016/j.cca.2015.10.034",

language = "English",

volume = "452",

pages = "50--7",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

TY - JOUR

T1 - Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

AU - van der Velde, A Rogier

AU - Lexis, Chris P H

AU - Meijers, Wouter C

AU - van der Horst, Iwan C

AU - Lipsic, Erik

AU - Dokter, Martin M

AU - van Veldhuisen, Dirk J

AU - van der Harst, Pim

AU - de Boer, Rudolf A

PY - 2016/1/15

Y1 - 2016/1/15

N2 - BACKGROUND: Fibrosis is a pivotal event in infarct repair and progressive remodeling after myocardial infarction (MI). Biomarkers may be used to monitor fibrosis, and therefore we evaluated the predictive value of galectin-3 and sST2 for cardiac remodeling after MI.METHODS: Plasma galectin-3 and sST2 were measured in patients admitted with primary percutaneous coronary intervention (PCI) for acute MI, at baseline and at 4months. Left ventricular ejection fraction (LVEF) and infarct size were measured after 4months with cardiac MRI (CMR).RESULTS: In total, 247 patients had blood samples and CMR data available (mean age 57.7±11.6years; 79.8% male). Increased baseline galectin-3 (≥17.8ng/mL) identified patients with lower LVEF (50.3% (±9.1) vs. non-elevated galectin-3 55.0% (±8.0); P<0.001), and larger infarct size (13.8g. (±12.9) vs. 8.6g. (±8.7); P=0.002) after 4months. Elevated sST2 (≥35.0ng/mL) did not predict decreased LVEF or larger infarct size. Furthermore we showed that at baseline, galectin-3 was an independent predictor for LVEF (β=-0.18; P=0.005) and infarct size (β=0.18; P=0.004). We repeated the analyses using median values of galectin-3 (13.4ng/mL) and sST2 (30.3ng/mL) as a cut point, and this validated our results.CONCLUSION: The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI.

AB - BACKGROUND: Fibrosis is a pivotal event in infarct repair and progressive remodeling after myocardial infarction (MI). Biomarkers may be used to monitor fibrosis, and therefore we evaluated the predictive value of galectin-3 and sST2 for cardiac remodeling after MI.METHODS: Plasma galectin-3 and sST2 were measured in patients admitted with primary percutaneous coronary intervention (PCI) for acute MI, at baseline and at 4months. Left ventricular ejection fraction (LVEF) and infarct size were measured after 4months with cardiac MRI (CMR).RESULTS: In total, 247 patients had blood samples and CMR data available (mean age 57.7±11.6years; 79.8% male). Increased baseline galectin-3 (≥17.8ng/mL) identified patients with lower LVEF (50.3% (±9.1) vs. non-elevated galectin-3 55.0% (±8.0); P<0.001), and larger infarct size (13.8g. (±12.9) vs. 8.6g. (±8.7); P=0.002) after 4months. Elevated sST2 (≥35.0ng/mL) did not predict decreased LVEF or larger infarct size. Furthermore we showed that at baseline, galectin-3 was an independent predictor for LVEF (β=-0.18; P=0.005) and infarct size (β=0.18; P=0.004). We repeated the analyses using median values of galectin-3 (13.4ng/mL) and sST2 (30.3ng/mL) as a cut point, and this validated our results.CONCLUSION: The fibrosis biomarker galectin-3, but not sST2, taken immediately after MI, predicts LVEF and infarct size after 4months. We hypothesize that galectin-3 may play a role in the pathophysiology of cardiac remodeling after acute MI.

KW - Biomarkers/blood

KW - Blood Proteins

KW - Double-Blind Method

KW - Female

KW - Galectin 3/blood

KW - Galectins

KW - Humans

KW - Interleukin-1 Receptor-Like 1 Protein

KW - Magnetic Resonance Imaging

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/blood

KW - Receptors, Cell Surface/blood

KW - Solubility

KW - Time Factors

KW - Ventricular Dysfunction, Left/blood

U2 - 10.1016/j.cca.2015.10.034

DO - 10.1016/j.cca.2015.10.034

M3 - Article

C2 - 26528636

SN - 0009-8981

VL - 452

SP - 50

EP - 57

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

ER -

Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

Abstract

Keywords

Access to Document

Fingerprint

Cite this